Linklaters has advised Amplex AB on its public cash offer for ADDvise Group AB (publ)

Linklaters advised Amplex AB on a public cash offer and its financing to acquire all four listed instruments of ADDvise Group AB (publ), valuing the international life‑science group at more than SEK 1 billion. ADDvise, which comprises over 20 companies across Lab and Healthcare, generates approximately SEK 1.7 billion in annual revenue; the offer constitutes a full takeover if accepted by shareholders. The deal, handled by Linklaters’ Stockholm team, represents a notable M&A transaction in the Nordic life‑sciences sector.

Analysis

Linklaters advised Amplex AB on a public cash offer and the financing to acquire all four listed instruments of ADDvise Group AB (publ), valuing ADDvise at more than SEK 1 billion. ADDvise is an international life‑science group comprising more than 20 companies across Lab and Healthcare and generates annual revenues close to SEK 1.7 billion. The offer covers all listed instruments and constitutes a full takeover if accepted by shareholders, indicating a comprehensive purchase structure.

The headline valuation of >SEK 1.0bn versus reported revenue of ~SEK 1.7bn implies a revenue multiple in the vicinity of ~0.6x, a modest multiple for life‑sciences transactions that may reflect asset mix, profitability or strategic pricing. Linklaters’ role on both the offer and its financing signals that Amplex has arranged legal and funding support to manage instrument‑level complexity and regulatory requirements.

Near‑term catalysts are the formal offer documentation, shareholder acceptances and any financing or regulatory conditions; failure to clear these would create deal risk. Market sentiment outputs are mildly positive (score 0.28) with limited immediate market impact (0.25); investors should watch the disclosed offer price, financing terms, and integration challenges across ADDvise’s 20+ subsidiaries.

Key Decisions for Investors

• For holders of ADDvise, await the formal offer document to assess the disclosed price and any premium before making a decision, consider selling into the offer if it represents a meaningful premium to pre‑offer levels
• Do not initiate material new positions in Amplex or ADDvise until shareholder acceptance, financing terms and regulatory approvals are public
• Use the disclosed transaction multiple as a near‑term valuation reference for Nordic life‑science peers and reassess relative valuations if the multiple proves lower than sector precedents
• Monitor Amplex’s financing disclosures and post‑deal capital structure for dilution or leverage risks and be prepared to hedge or reduce exposure if financing is conditional or materially dilutive